A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
Launched by PFIZER · Feb 19, 2008
Trial Information
Current as of May 02, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female of any race at least 18 years of age
- • Diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy, which is due to diabetes, for at least 1 year
- • Patients at Visit 1 must have a score ≥40 mm on the Pain Visual Analogue Scale
- Exclusion Criteria:
- • Patients with significant hepatic impairment
- • Neurological disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathic pain
- • Any pain or other condition that may confound assessment or self-evaluation of the pain due to diabetic neuropathy
- • Amputations other than toes
- • A current or recent diagnosis (past 6 months) or episode of major depressive disorder and/or uncontrolled depression
- • History of transient ischemic attack or stroke
- • Myocardial infarction or unstable angina within the past three months
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Springfield, Missouri, United States
Birmingham, Alabama, United States
Amsterdam, , Netherlands
Madrid, , Spain
Valencia, , Spain
Jackson, Mississippi, United States
Barcelona, , Spain
Lexington, Kentucky, United States
Waterbury, Connecticut, United States
Tupelo, Mississippi, United States
Dallas, Texas, United States
L'hospitalet De Llobregat, Barcelona, Spain
Louisville, Kentucky, United States
Denver, Colorado, United States
New Britain, Connecticut, United States
Beaumont, Texas, United States
Houston, Texas, United States
Milwaukee, Wisconsin, United States
Myrtle Beach, South Carolina, United States
North Dartmouth, Massachusetts, United States
Buffalo, New York, United States
Bartlett, Tennessee, United States
New York, New York, United States
Lahti, , Finland
Tampa, Florida, United States
Cranston, Rhode Island, United States
Santiago De Compostela, La Coruña, Spain
Anniston, Alabama, United States
Lohja, , Finland
Cumberland, Rhode Island, United States
Zlin, , Czechia
Bloemfontein, Free State, South Africa
Ceske Budejovice, , Czechia
Mission Viejo, California, United States
Hamilton, New Jersey, United States
Venlo, , Netherlands
Brno, , Czechia
Almere, , Netherlands
Helsinki, , Finland
Winter Haven, Florida, United States
Marionville, Missouri, United States
Elizabeth, New Jersey, United States
Ostrava, , Czechia
Kokkola, , Finland
Worcester, Cape Town, South Africa
Ennerdale, Gauteng, South Africa
Tshwane, Gauteng, South Africa
Stanger, Kwa Zulu Natal, South Africa
Durban, Kwazulu Natal, South Africa
Cape Town, , South Africa
Pontevedra, , Spain
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials